By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

RegeneRx Biopharmaceuticals, Inc. 

3 Bethesda Metro Center, Suite 630

Bethesda  Maryland  20814  U.S.A.
Phone: 301-280-1992 Fax: 301-280-1996


SEARCH JOBS








Company News
RegeneRx Biopharmaceuticals, Inc. (RGRX) Meeting With Institutional Investors And Analysts At BIO CEO Conference 2/1/2016 8:43:22 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial 1/29/2016 6:54:43 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX)'s TB4 Shown To Promote Regeneration And Repair Of Damaged Central Nervous System Cells 1/27/2016 6:44:16 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX)'s RGN-259 Phase II Meets Key Efficacy Objectives 12/23/2015 8:28:25 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Chinese Patent for Key TB4 Peptide Fragment 12/4/2015 9:39:27 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Analyst Report Update Issued By SeeThruEquity, LLC 10/29/2015 7:39:16 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Updates On U.S. Ophthalmic Clinical Trials 10/21/2015 10:21:48 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX)''s TB4 Shown To Significantly Limit Brain Damage After Stroke By Upregulating Microrna-200a 10/20/2015 12:01:12 PM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives $500,000 Milestone Payment With Enrollment Of First Patient In U.S. Phase 2b/3 Dry Eye Trial 10/1/2015 6:51:59 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces First Patient Enrolled In Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial With RGN-259 9/21/2015 11:49:03 AM
12345678910...
//-->